LeMaitre Provides Q2 2021 Update
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced preliminary Q2 2021 results, reporting net sales of $40.7 million, a 64% increase compared to Q2 2020, with organic growth of 35%. Operating income reached approximately $10.9 million to $11.3 million, up 128%. The gross margin declined to 65.5%-66.1%, impacted by inventory write-downs and manufacturing inefficiencies. Geographic sales growth was strong across all regions, especially in the Americas (+83%). Cash and cash equivalents stood at $21.8 million, while debt decreased by $9 million to $23 million.
- Net sales increased by 64% to $40.7 million compared to Q2 2020.
- Operating income rose by 128% to approximately $10.9 million to $11.3 million.
- Sales growth driven by Artegraft ($6.7 million), valvulotomes, shunts, and allografts.
- Strong geographic sales growth: Americas +83%, Europe/Middle East/Africa +36%, Asia/Pac +29%.
- Cash and cash equivalents increased to $21.8 million.
- Debt reduced by $9 million to $23 million.
- Gross margin decreased by 2.7% from Q2 2020 due to inventory write-downs and manufacturing inefficiencies.
BURLINGTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices, implants and services, today announced preliminary unaudited results for the quarter ended June 30, 2021.
Q2 2021 Preliminary Results
- Net Sales of
$40.7m m, +64% reported, +35% organic vs. Q2 2020 - Gross Margin of
65.5% to66.1% , -2.7% at the midpoint vs. Q2 2020 - Operating Income of approximately
$10.9m m to$11.3m m, +128% at the midpoint vs. Q2 2020 - Cash and Cash Equivalents of
$21.8 million - Debt paid down
$9m m to$23.0m m
By product, Q2 sales growth was driven by Artegraft (acquired in June 2020) with sales of
The gross margin decline was driven by inventory write-downs, as well as manufacturing inefficiencies related to personnel reductions in 2020.
The increase in income from operations was driven primarily by the increase in net sales in the period.
About LeMaitre Vascular
LeMaitre is a provider of devices for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. LeMaitre Vascular develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.
LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.
For more information about the Company, please visit http://www.lemaitre.com.
Use of Non-GAAP Financial Measures
LeMaitre management believes that in order to better understand the Company's short-term and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. Reconciliation of GAAP to non-GAAP results is provided below.
In this press release, the Company has reported its non-GAAP sales growth percentage after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events as well. The Company refers to the calculation of non-GAAP sales growth percentages as "organic." The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management.
The Company has also reported non-GAAP outstanding debt, which takes into account the impact of unamortized deferred financing costs. The Company believes that considering its debt in this manner provides a view of the amount owed on a cash basis.
| Reconciliation between GAAP and Non-GAAP net sales growth (unaudited, $ in thousands) | |||
| For the three months ended June 30, 2021 | |||
| Preliminary net sales as reported | |||
| Preliminary impact of currency exchange fluctuations | (1,186) | ||
| Preliminary net impact of acquisitions excluding currency | (5,982) | ||
| Preliminary adjusted net sales | |||
| For the three months ended June 30, 2020 | |||
| Net sales as reported | |||
| Adjusted net sales | |||
| Preliminary adjusted net sales increase for the three months ended June 30, 2021 | |||
| Reconciliation between GAAP and Non-GAAP debt outstanding (unaudited, $ in thousands) | |||
| As of June 30, 2021 | |||
| Debt as reported | |||
| Add back unamortized deferred financing costs | 552 | ||
| Adjusted debt outstanding | |||
Preliminary Financial Results
The estimates above represent the most current information available to the Company and do not present all information necessary for an understanding of the Company’s financial condition as of and the results of operations for the three months ended June 30, 2021. The Company has provided an estimate for the preliminary and unaudited results described above primarily because the Company’s financial closing procedures for the three months ended June 30, 2021 are not yet complete. As a result, there is a possibility that the Company’s final results will vary materially from these preliminary estimates as a result of the completion of normal quarter-end accounting procedures and adjustments, including the execution of the Company’s internal control over financial reporting, the completion of the preparation and review of the Company’s financial statements for the three months ended June 30, 2021 and the subsequent occurrence or identification of events prior to the formal issuance of the Company’s financial results for the three months ended June 30, 2021. We undertake no obligation to update or supplement the information provided above until the Company releases its results of operations for the three months ended June 30, 2021.
The preliminary estimates for the three months ended June 30, 2021 presented above have been prepared by, and are the responsibility of, the Company’s management. The Company’s independent registered public accounting firm has not audited, reviewed, compiled, or performed any procedures with respect to such preliminary information. Accordingly, the Company’s independent registered public accounting firm does not express an opinion or any other form of assurance with respect thereto.
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding LeMaitre, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Litigation Reform Act of 1995, including the preliminary unaudited results contained herein. Such forward-looking statements involve substantial risks and uncertainties that could cause LeMaitre’s future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all. LeMaitre undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to LeMaitre’s business in general, please refer to LeMaitre’s Annual Report on Form 10-K filed with the SEC on March 12, 2021, LeMaitre’s Quarterly Report on Form 10-Q filed with the SEC on May 10, 2021, and LeMaitre’s other periodic reports filed with the SEC.
Investor Relations Contacts:
| David Roberts | J.J. Pellegrino |
| President | Chief Financial Officer |
| LeMaitre Vascular, Inc. | LeMaitre Vascular, Inc. |
| 781-425-1693 | 781-425-1691 |
| droberts@lemaitre.com | jpellegrino@lemaitre.com |
FAQ
What were LeMaitre Vascular's preliminary Q2 2021 net sales?
How much did LeMaitre Vascular increase its operating income in Q2 2021?
What factors contributed to LeMaitre Vascular's sales growth in Q2 2021?
How did LeMaitre Vascular's gross margin change in Q2 2021?
What were the geographical sales growth figures for LeMaitre Vascular in Q2 2021?
